Treatment of X-linked lymphoproliferative disease (Duncan disease) with high-dose methylprednisolone and etoposide (VP-16).

Abstract	A five-year-old boy in the acute phase of X-linked lymphoproliferative (XLP) syndrome (Duncan disease) with high fever and hepatosplenomegaly was treated successfully with high-dose methylprednisolone and VP-16 for 15 months. He had been alive for four years after diagnosis as of this writing. We recommend high-dose methylprednisolone and VP-16 in patients with XLP who have to wait for a suitable donor before bone marrow transplantation.
Authors	A Gürgey, T Sayli, A Kara, G Kale, I Berkel
Journal	The Turkish journal of pediatrics (Turk J Pediatr) 1996 Apr-Jun Vol. 38 Issue 2 Pg. 217-22 ISSN: 0041-4301 [Print] Turkey
PMID	8701487 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Anti-Inflammatory Agents Antineoplastic Agents, Phytogenic Etoposide Methylprednisolone
Topics	Anti-Inflammatory Agents (therapeutic use) Antineoplastic Agents, Phytogenic (therapeutic use) Child, Preschool Drug Therapy, Combination Etoposide (therapeutic use) Humans Infant Lymphoproliferative Disorders (drug therapy, genetics) Male Methylprednisolone (therapeutic use) Pedigree Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!